Hologic Q2 2023 Earnings Report
Key Takeaways
Hologic reported a decrease in revenue by 28.5% to $1,026.5 million, primarily due to lower COVID-19 assay sales. Excluding COVID-19 revenues, total organic revenue grew by 20.2%. The company's GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.06, both exceeding guidance. Hologic raised its fiscal year 2023 revenue and EPS guidance.
Revenue decreased by 28.5% to $1,026.5 million, but exceeded prior guidance.
Excluding COVID-19 revenues, total organic revenue grew by 20.2%.
GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.06, both exceeding guidance.
The company raised its fiscal year 2023 revenue and EPS guidance.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Forward Guidance
Hologic raised its full-year guidance for both revenue and EPS, highlighting confidence in the remainder of the fiscal year despite an uncertain macro environment.
Revenue & Expenses
Visualization of income flow from segment revenue to net income